Contact Us
Drug Search Results
More Filters [+]

Azeliragon

Alternative Names: azeliragon, ttp488, pf-04494700
Latest Update: 2024-12-09
Latest Update Note: News Article

Product Description

Azeliragon is an oral, small-molecule inhibitor of RAGE, a cell-surface receptor of the immunoglobulin superfamily. (Sourced from: https://www.alzforum.org/therapeutics/azeliragon)

Mechanisms of Action: RAGE Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Orphan Drug - Glioblastoma
Orphan Drug - Pancreatic Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: vTv
Company Location: HIGH POINT NC 27265
Company CEO: Paul J. Sekhri
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Azeliragon

Countries in Clinic: Spain, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Brain Cancer|Glioblastoma|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2022-002801-36

P2

Active, not recruiting

Glioblastoma

2026-03-01

ADORATION

P2

Recruiting

Brain Cancer

2025-10-01

CAN-201 MPC

P2

Recruiting

Pancreatic Cancer

2025-02-01

57%
CAN 201

P2

Active, not recruiting

Glioblastoma

2024-12-01

Recent News Events

Date

Type

Title

12/09/2024

News Article

 CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

05/28/2024

News Article

 CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

05/20/2024

News Article

 CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER

04/01/2024

PubMed

 S100b treatment overcomes RAGE signaling deficits in myoblasts on advanced glycation end-product cross-linked collagen and promotes myogenic differentiation.

03/19/2024

News Article

 CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

02/08/2024

PubMed

 Macrophage RAGE activation is proinflammatory in NASH.

07/13/2023

PubMed

 RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions